Earnings summaries and quarterly performance for Entrada Therapeutics.
Executive leadership at Entrada Therapeutics.
Board of directors at Entrada Therapeutics.
Research analysts covering Entrada Therapeutics.
Recent press releases and 8-K filings for TRDA.
Entrada Therapeutics Provides Update on Clinical Programs and Financial Outlook
TRDA
Guidance Update
New Projects/Investments
- Entrada Therapeutics (TRDA) is a clinical-stage biotech company focused on developing therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), leveraging its proprietary Endosomal Escape Vehicle (EEV) technology platform.
- The company reported a cash position of $354 million, which is projected to provide an operational runway into Q2 2027.
- Key clinical data catalysts are anticipated in 2026: initial patient data for the DMD exon 44 program (ENTR-601-44) in H1 2026, and for the DMD exon 45 program (ENTR-601-45) in mid-2026.
- The DM1 program (VX-670), developed in partnership with Vertex Pharmaceuticals, is expected to complete dosing and enrollment of its multiple ascending dose (MAD) portion in 2026. Vertex initially paid $224 million for this preclinical asset.
- Entrada's EEV platform is highlighted for its ability to achieve high target engagement with low doses and low manufacturing costs, offering a flexible therapeutic approach that differentiates it from competing and current therapies, particularly in the DMD landscape where gene therapies have encountered challenges.
Sep 25, 2025, 2:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more